Why the study?
Total coronary atherosclerosis measured by quantitative coronary CT is an emerging marker of cardiovascular risk, but the risk and absolute event rates across plaque volume staging systems and clinical likelihood of obstructive CAD needed evaluation.
Does total plaque volume measured by AI-QCT predict major adverse cardiovascular events in symptomatic patients undergoing coronary CT angiography?
Does total plaque volume measured by AI-QCT predict major adverse cardiovascular events in symptomatic patients undergoing coronary CT angiography?
Total plaque volume quantified by AI-QCT is a strong predictor of cardiovascular events in symptomatic patients, with risk increasing significantly from 250 mm³ of TPV regardless of clinical likelihood for obstructive CAD.
May aid risk stratification via plaque volume in coronary CT; leaves open incremental value over clinical CAD likelihood in prospective studies.
Introduction The totality of atherosclerosis from the coronary tree can be measured with quantitative coronary CT and is increasingly being recognized as important marker for future cardiovascular events. We evaluated the risk and absolute event rates of plaque volume staging systems and provided analyses according to the clinical likelihood of obstructive CAD. Methods CONFIRM2 is an ongoing, global, multicenter, observational registry that included patients with clinically indicated coronary CT angiography and follow-up for major adverse cardiovascular events (MACE). Patients without cardiac symptoms and prior CAD were excluded. Atherosclerosis was quantified across all coronary segments by AI-QCT. Total plaque volume (TPV) was categorized into non-calcified plaque (NCPV, HU <350) and calcified (HU>350). The primary end point was the incidence rate of MACE over at 4 years and included all-cause mortality, myocardial infarction, stroke, congestive heart failure, late revascularizations (occurring >90 days post index CCTA), and hospitalization for unstable angina. Secondary endpoint included Death, MI, and stroke. The prognostic value of TPV and NCPV was evaluated across the pretest likelihood according to the ESC Risk Factor Weighted Likelihood (ESC RF-CL). Results A total of 6,061 patients (mean age 58.6 ± 12.1 years, 48.6% male) were included and the mean follow-up duration was: 4.4±1.8 years. According to the ESC RF-CL for obstructive CAD, patients were classified as very-low, low, and moderate risk in 36.0%, 43.0%, and 22.0%, and obstructive CAD rates were 6.8%, 15.7%. and 28.2, respectively. Within the total cohort, TPV >0-250, 250-750, and >750mm 3 were associated with MACE: HR 2.5 (95% CI 1.1, 5.6), HR 10.1 (95% CI 4.4, 22.9), and HR 15.9 (95% CI 6.7, 38.0) compared with TPV=0. According to RF-CL very-low, low, and moderate, the MACE rates were: 0.7, 2.9, 0.0% for TPV=0mm 3 ; 2.3%, 3.6%, 4.6% for TPV >0-250mm 3 ; 10.3%, 12.3%, 13.5% for TPV 250-750mm 3 ; and 18.8%, 16.7%, and 19.8% for TPV>750mm 3 . Findings were consistent for the secondary endpoint. Conclusion Among a large cohort of symptomatic patients evaluated by coronary CT angiography, the burden of atherosclerosis by AI-QCT was the main driver for cardiovascular events. Absolute event rates were consistently higher by each plaque volume stage, and consistent across the clinical likelihood subgroups for obstructive CAD. While quantitative atherosclerosis was present in the majority of patients, risk increased significantly from 250mm 3 of TPV during intermediate term follow-up.
No takes yet. Share an insight, caveat, or question.
Rosendael et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: